FOR OPTIONEES IN U.S.) CASI Pharmaceuticals, Inc. 2011 Long-Term Incentive Plan Non-Qualified Stock Option Grant AgreementNon-Qualified Stock Option Grant Agreement • May 15th, 2019 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Maryland
FOR OPTIONEES IN CHINA) CASI Pharmaceuticals, Inc. 2011 Long-Term Incentive Plan Non-Qualified Stock Option Grant AgreementNon-Qualified Stock Option Grant Agreement • May 15th, 2019 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Maryland
EXCLUSIVE DISTRIBUTION AGREEMENTExclusive Distribution Agreement • May 15th, 2019 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
CASI Pharmaceuticals INC., (“CASI”) a Nasdaq listed company incorporated and existing under the laws of the State of Delaware, USA with its registered domicile at 9620 Medical Center Drive in Rockville, MD USA.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. ***Triple asterisks denote omissions.License Agreement • May 15th, 2019 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
This License Agreement (this “Agreement”) is entered into as of April 16, 2019 (the “Effective Date”) by and between Black Belt therapeutics Limited, having a place of business at Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire, United Kingdom SG1 2FX (“Black Belt”), and CASI Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 9620 Medical Center Drive, Suite 300, Rockville, MD 20850 (“CASI”). Black Belt and CASI are sometimes referred to individually as a “Party” and collectively as the “Parties.”
